



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 18541

Title: Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer: Minireview

Reviewer's code: 00182276

Reviewer's country: Hungary

Science editor: Ya-Juan Ma

Date sent for review: 2015-04-24 15:23

Date reviewed: 2015-06-07 20:21

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Very good overview of anti EGFR studies.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 18541

Title: Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer: Minireview

Reviewer's code: 00053417

Reviewer's country: China

Science editor: Ya-Juan Ma

Date sent for review: 2015-04-24 15:23

Date reviewed: 2015-06-07 21:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this mini-review, the authors try to summarize the data on the topic of anti EGFR therapy in colorectal cancer. There are some reservations about the study: 1 As the title is too big, the contents of this mini-review do not fully cover the scope of the title. 2 Writing skills need improvement e.g. tables are usually required in a review article; key words should be provided in abstract; accuracy is important such as EGFR=epidermal growth factor receptor, but not epidermal growth receptor 3 The related work has been published. A similar review article has been published in this journal (World J Gastroenterol. 2014 Apr 21;20:4263-75).



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 18541

Title: Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer: Minireview

Reviewer’s code: 00159843

Reviewer’s country: South Korea

Science editor: Ya-Juan Ma

Date sent for review: 2015-04-24 15:23

Date reviewed: 2015-06-12 12:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

ESPS Manuscript Number: 18541 Title: Anti EGFR therapy in colorectal cancer In this study, an author summarized the results of recently published papers that the mechanism and clinical effect of anti-EGFR treatment in colorectal cancer. This review study is informative and acceptable in World Journal of Gastroenterology for readers. However, this manuscript will be more improve with some modification. Main subject, 1. Author did not review about one of another main anti-EGFR therapy (BRAF or RAF by Vemurafenib) in CRC. This reviewer suggests that author has to summarize briefly about it. 2. If possible, the results of anti-EGFR therapies in CRC are summarized with Table or Figure. Minor subject, 1. This manuscript has the many of typing and space errors. 2. There are no full names for abbreviated words through this manuscript.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 18541

Title: Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer: Minireview

Reviewer's code: 00058482

Reviewer's country: Spain

Science editor: Ya-Juan Ma

Date sent for review: 2015-04-24 15:23

Date reviewed: 2015-06-19 23:44

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

We have a review about the mechanism and clinical effect of anti-EGFR therapy in colorectal cancer. Some modifications are needed for publication. -Since manuscript is focused in the mechanism of resistance to anti-EGFR therapy, this issue must be included in the title. -A table summarizing the more important clinical trial and results might be included - Nowadays, difference between KRAS and RAS is well established. ... Based on this knowledge, KRAS mutations status is now mandatory for treatment of metastatic CRC with anti-EGFR based treatment.... - ... NORDIC-VII study, cetuximab did not add significant benefit in first... - ...[30]. Approximately %5-9 of CRC are characterized by a specific mutation in BRAF...